Cho, Chang-Soo
Jeong, Hye-Seong
Kim, In-Young
Jung, Go-Woon
Ku, Bon-Hwa
Park, Dong-Chan
Moon, Seung-Bae
Cho, Hyung-Rae
Bashir, Khawaja Muhammad Imran
Ku, Sae Kwang
Choi, Jae-Suk http://orcid.org/0000-0002-8151-6054
Funding for this research was provided by:
Ministry of Trade, Industry and Energy (R0005614)
Article History
Received: 3 April 2018
Accepted: 25 October 2018
First Online: 6 November 2018
Ethics approval and consent to participate
: All laboratory animals were treated according to the national regulations for the usage and welfare of laboratory animals, and approved by the Institutional Animal Care and Use Committee of Daegu Haany University, Gyeongsan, Gyeongbuk-do, Republic of Korea, prior to animal experiments [Approval No: DHU2016–072; Approved on: August 23, 2016]. In addition, experiments on osteoporosis were conducted based on the United States Food and Drug Administration (FDA) Guidelines for Preclinical Evaluation of Agents Used in The Prevention or Treatment of Postmenopausal Osteoporosis [April 1994, Division of Metabolic and Endocrine Drug Products, USA].
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.